Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.48 CAD -0.17 ( 1.76%)
Last update at 2026-11-04T20:33:00Z
VOLUME
62250
Market Cap
592.28M

Momentum Score

…

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.25
Low
9.84
High
52 Week Price Range
5.01
Low
12.86
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eupraxia Pharmaceuticals Inc (EPRX.TO) is a Toronto-listed company; available filings provide limited detail on its operations and product pipeline. As a small-cap pharmaceutical issuer, its long-term growth would typically depend on successful clinical or regulatory milestones, strategic partnerships, and access to financing, which may benefit shareholder value if achieved.

Key risks include typical early-stage pharmaceutical execution and regulatory uncertainty, reliance on external capital, and low trading liquidity that could amplify share volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.65
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-68.76%
Net Debt
-80.26M
ROCE
-48.66%
Diluted EPS TTM
-1.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -39.26M -35.27M -39.18M -23.92M -23.37M
Minority interest 0.03M 0.24M 0.75M 0.66M 0.38M
Net income -39.25M -34.94M -37.39M -23.26M -22.99M
Selling general administrative 17.10M 15.71M 9.65M 5.53M 8.41M
Selling and marketing expenses - - 0.14M - -
Gross profit -0.24M -0.24M -0.21M - -
Reconciled depreciation 0.24M 0.17M 0.16M 0.19M 0.11M
Ebit -39.11M -33.95M -37.61M -23.20M -18.20M
Ebitda -38.86M -33.72M -37.40M -22.14M -21.96M
Depreciation and amortization 0.24M 0.24M 0.21M - -
Operating income -39.11M -36.99M -36.90M -23.24M -20.97M
Other operating expenses 39.11M 36.99M 37.92M - -
Interest expense 0.00M 1.31M 1.58M 1.59M 1.30M
Tax provision 0.02M 0.00M 0.04M - -
Interest income 1.41M 1.24M 0.86M 0.67M 2.40M
Net interest income 1.41M 0.56M -0.31M -1.02M -1.23M
Income tax expense 0.02M 0.00M -0.09M - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 38.86M 36.76M 37.92M 23.20M 18.68M
Cost of revenue 0.24M 0.24M 0.21M - -
Total other income expense net -0.16M 1.73M -2.29M 0.31M -3.46M
Net income from continuing ops -38.61M -25.74M -28.97M -23.92M -23.37M
Net income applicable to common shares - -25.50M -28.22M -23.26M -22.99M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 85.99M 34.94M 26.72M 25.88M 31.22M
Other current assets 3.85M - 0.36M - -
Total liab 5.69M 3.10M 25.55M 13.02M 10.84M
Total stockholder equity 81.89M 33.40M 2.92M 12.86M 20.39M
Other current liab 5.54M - 11.76M - 0.01M
Common stock 195.05M - 122.52M 92.34M 80.71M
Capital stock 225.15M 148.07M 92.91M 92.34M 80.71M
Retained earnings -169.27M -131.00M -139.11M -97.45M -74.19M
Other assets - - 0.00M 0.00M 0.03M
Cash 80.42M 33.10M 25.50M 24.74M 20.89M
Total current liabilities 5.62M 3.10M 25.55M 4.14M 2.27M
Net debt -80.26M - -11.72M - -
Short term debt 0.08M - 13.78M 0.00M 0.00M
Short long term debt - - 10.40M 0.11M 0.09M
Short long term debt total 0.15M - 13.78M - -
Other stockholder equity 28.47M - 23.09M 17.96M 13.86M
Property plant equipment - - - 0.70M 0.59M
Total current assets 84.94M 34.44M 26.11M 25.18M 30.60M
Net tangible assets - - - 12.86M 20.39M
Short term investments - - - 0.00M 9.01M
Net receivables 0.67M - 0.25M 0.12M 0.43M
Long term debt - - - 10.30M 9.26M
Inventory - - 0.00M - -
Accumulated other comprehensive income -2.04M - -3.57M - -
Non currrent assets other 0.06M - 0.01M - -
Non current assets total 1.05M 0.51M 0.61M 0.70M 0.62M
Capital lease obligations 0.15M 0.07M 0.05M 0.14M 0.20M
Long term debt total - - - 10.37M 9.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.08M -0.07M 9.01M -9.00M
Change to liabilities - - - 1.78M -0.47M
Total cashflows from investing activities -0.60M -0.08M -0.10M 8.70M -14.45M
Net borrowings 0.00M -9.14M -0.08M -0.19M 12.08M
Total cash from financing activities 77.39M 45.78M 27.84M 13.52M 49.92M
Change to operating activities - - - -0.02M 0.07M
Net income -39.25M -25.74M -37.39M -23.26M -22.99M
Change in cash 45.75M 13.76M 1.08M 3.84M 20.74M
Begin period cash flow 34.67M 19.34M 18.26M 20.89M 0.15M
End period cash flow 80.42M 33.10M 19.34M 24.74M 20.89M
Total cash from operating activities -29.05M -29.99M -27.92M -18.78M -14.64M
Issuance of capital stock 73.89M 54.56M 15.89M 13.30M 37.83M
Depreciation 0.24M 0.24M 0.16M 0.19M 0.11M
Other cashflows from investing activities - 0.03M -0.00M 9.01M -5.02M
Change to inventory - - -0.58M - -
Change to account receivables -0.44M -0.10M -0.14M 0.31M 0.19M
Sale purchase of stock - 54.92M 21.16M 13.71M 37.83M
Other cashflows from financing activities - 0.36M 12.10M - 0.00M
Change to netincome - - - 2.22M 8.45M
Capital expenditures 0.60M 0.10M 0.07M 0.31M 0.43M
Change in working capital -0.73M -6.76M 6.33M 2.07M -0.18M
Stock based compensation 9.04M 3.22M 1.41M 2.02M 4.21M
Other non cash items 10.68M -0.94M 1.58M 1.16M 3.41M
Free cash flow -29.65M -30.10M -28.02M -19.08M -15.07M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 -6.36
SVA
Sernova Corp		 -0.01
4.35%		 0.11 - - 65.86 24.15 -11.27

Profile*

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4

250 590 3968

https://www.eupraxiapharma.com

49

Name Title Year Born
Dr. James A. Helliwell FRCPC, M.D. CEO & Director 1974
Mr. Bruce G. Cousins CPA, C.A., CPA Pres & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Bus. Officer NA
Mr. Bruce G. Cousins C.A., CPA President & CFO 1961
Dr. Amanda Malone Ph.D. Chief Scientific Officer & COO 1981
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Business Officer NA
Dr. Mark M. Kowalski M.D., Ph.D. Chief Medical Officer 1955
Dr. Rahul Sarugaser M.B.A., Ph.D. Executive Vice President of Corporate Development NA
Mr. Alexander John Rothwell Eng., M.B.A. Chief Financial Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…